GlassScriptPhysician profile
Alyce R Adams
NPI 1700806767
$9,578.15
in general payments reported to CMS, 2019-2025
29 companies · $667 in 2025
The $667 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $137 · 2021: $346 · 2022: $737 · 2023: $6,589 · 2024: $598 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,336 · Food and Beverage: $1,947 · Travel and Lodging: $1,526 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,336.00 |
| Food and Beverage | $1,947.34 |
| Travel and Lodging | $1,525.59 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $5,947.47 | 2019-2023 | Dexcom G7 Gss (161) |
| Lilly USA, LLC | $584.42 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $477.42 | 2022-2025 | |
| Novo Nordisk INC | $472.60 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $302.37 | 2019-2024 | Airsupra |
| Insulet Corporation | $294.53 | 2019-2025 | Omnipod, Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.98 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $213.49 | 2019-2025 | |
| Genzyme Corporation | $176.65 | 2020-2024 | |
| Esperion Therapeutics, INC. | $138.09 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $117.40 | 2023 | Quviviq |
| Abbvie INC. | $88.67 | 2024-2025 | |
| Abbott Laboratories | $83.86 | 2023-2025 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $58.38 | 2023 | Shingrix, Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $50.47 | 2024 | Gvoke Hypopen |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $50.19 | 2024-2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $43.60 | 2019-2022 | |
| Inspire Medical Systems, INC. | $36.18 | 2025 | Inspire |
| Neurelis, INC. | $32.68 | 2024 | Valtoco |
| Amgen INC. | $29.86 | 2019 | |
| Dynavax Technologies Corporation | $25.00 | 2024 | Heplisav-B |
| Phathom Pharmaceuticals, INC. | $22.78 | 2024 | Voquezna |
| Astellas Pharma US INC | $20.55 | 2023 | Veozah |
| Lexicon Pharmaceuticals, INC. | $19.56 | 2023 | Inpefa |
| Ironwood Pharmaceuticals, INC | $17.66 | 2023 | Linzess |
| Sanofi-Aventis U.S. LLC | $14.64 | 2023 | |
| Avanir Pharmaceuticals, INC. | $14.61 | 2019 | |
| Lundbeck LLC | $13.63 | 2025 | Rexulti |
| Amarin Pharma, INC. | $13.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyce Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.